RE:RE:Pfizer acquired preclinical Trillium for US$ 2.3 BlnJanuary 26, 2022 : "....Gilead, ... has halted some studies of its anti-CD47 project magrolimab after seeing adverse events. This is another blow to Gilead’s deal strategy - it paid $4.9 bn for Forty Seven's (CD47) magrolimab in 2020 – but the news could also make Pfizer nervous. The pharma giant recently made its own CD47 move buying Trillium for $2.3bn" https://www.evaluate.com/vantage/articles/news/policy-and-regulation-snippets/pfizer-hopes-gileads-cd47-issues-arent
In September 2020 AbbVie entered the CD47 space with a $2 billion upfront- biobucks R&D deal with Shanghai-based I-Mab, granting the U.S. company with access to the anti-CD47 monoclonal antibody lemzoparlimab.
Then in .... July 21, 2022 - " ... I-Mab was forced to defend Abbvie’s decision to terminate a multiple myeloma trial of lemzoparlimab, the groups’ joint anti-CD47 MAb whose clinicaltrials.gov listing was recently marked “terminated (strategic considerations)...” https://www.evaluate.com/vantage/articles/news/snippets/cd47-blockade-continues-its-bumpy-journey
January 11, 2023 - " As 2023 got under way investors in Novartis and Gilead might have been looking for pleasant surprises from interim analyses of two key studies. Such hopes have been dashed, according to updates slipped out at the JP Morgan healthcare conference this week.
... the Enhance trial of Gilead’s anti-CD47 MAb magrolimab in first-line high-risk myelodysplastic syndromes had an expected first interim analysis in the current quarter, but this too has passed without triggering a halt for efficacy. The CD47 mechanism has disappointed, and Enhance's focus now turns to a second interim analysis in the second half of the year." https://www.evaluate.com/vantage/articles/events/conferences-snippets/jp-morgan-2023-novartis-and-gileads-interim-halt-hopes